rivaroxaban


Also found in: Medical, Wikipedia.
Related to rivaroxaban: Apixaban, Pradaxa, Dabigatran
Translations

rivaroxaban

n rivaroxabán m
References in periodicals archive ?
13] Unlike vitamin K antagonists like warfarin, rivaroxaban does not require frequent monitoring, but is dosed-based on creatinine clearance and does not have a reversible antidote.
After decades as the lone anticoagulant defender against strokes from atrial fibrillation (Afib) or blood clots in the legs (deep vein thrombosis, DVT) or lungs (pulmonary embolism), warfarin has company from three other drugs: dabigatran (Pradaxa), rivaroxaban (Xarelto) and apixaban (Eliquis).
El estudio ROCKET-FA (17) consistio en un ensayo clinico de no inferioridad, doble ciego, que aleatorizo 14 264 pacientes con FA no valvular y riesgo moderado-alto de ictus, a recibir rivaroxaban 20 mg una vez al dia (15 mg si la depuracion de creatinina estaba entre 30 y 49 mL/min) o warfarina (INR objetivo: 2 a 3), con seguimiento de 1,94 anos y un promedio de edad de 73 anos; el 60,3% de los pacientes fue varon.
Rivaroxaban is an oral direct factor Xa inhibitor with a competitive and reversible binding effect to factor Xa.
In this issue of Clinical Chemistry, Helin and colleagues report their findings when normal pooled plasmas, spiked with dabigatran (the active metabolite of dabigatran etexilate, a DTI), or rivaroxaban (a DFXaI) were sent to laboratories participating in a European external quality assessment program (3).
Dabagitran (Pradaxa) and rivaroxaban (Xarelto) are newer anticoagulants; designed to minimize the risks of warfarin, they do not require frequent monitoring.
The advent of newer agents like Dabigatran, direct factor IIa (thrombin) inhibitor and Apixaban and Rivaroxaban, Factor Xa inhibitors may make this a little easier.
The recommendation by the CHMP to approve rivaroxaban for this additional use is an important milestone towards improved patient management in the treatment of pulmonary embolism,' said Dr.
By the time of its completion, more than 75,000 patients will have participated in the rivaroxaban clinical development program.
Scientists compared the effects of warfarin - the standard treatment to prevent clotting for irregular heartbeats - with the drug rivaroxaban.
But rivaroxaban is twice as effective at blocking fatal brain bleeds and has fewer side effects, experts from Edinburgh University and North Carolina's Duke University found.
The J-ROCKET AF study of rivaroxaban is the first and only pivotal, randomized, double-blind, double-dummy trial that has been undertaken in Japanese patients with atrial fibrillation, conducted with a Japan-specific dose and in full recognition of the Japanese Guideline environment.